Biomarker & Intervention Discovery
Glaucoma
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs29.0KWHO GHE 2021 · all ages
Global DALYs748.3KWHO GHE 2021 · worldwide
US mortality2 deaths/yrWHO GHE 2021
Global mortality69.3 deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionProgressive optic nerve damage without treatment; average visual field loss 0.5-1.0 dB/year; blindness in 10-20%…
Best-intervention remissionIOP-lowering drops: 20-30% IOP reduction; OHTS trial showed 50% risk reduction for glaucoma development in ocular…
Gap sizeModerate — IOP control is achievable but compliance is the dominant barrier; neuroprotection remains an unmet need
Primary barrierbiological (neuroprotection) + practice (adherence)
Full remission profile →
Remission & chronicity
Spontaneous remission
Progressive optic nerve damage without treatment; average visual field loss 0.5-1.0 dB/year; blindness in 10-20% without treatment; no spontaneous recovery of lost vision
Best-intervention remission
IOP-lowering drops: 20-30% IOP reduction; OHTS trial showed 50% risk reduction for glaucoma development in ocular hypertension; SLT (selective laser trabeculoplasty): IOP reduction 25-30%, equivalent to drops at 3 years (LiGHT trial); trabeculectomy: 35-45% IOP reduction, superior to drops in advanced disease
Gap size
Moderate — IOP control is achievable but compliance is the dominant barrier; neuroprotection remains an unmet need
Primary barrier
biological (neuroprotection) + practice (adherence)
IOP-lowering prevents further damage but cannot restore lost vision; adherence to drop therapy is poor (50-70% of patients non-adherent at 1 year); SLT (laser) as first-line (recommended by LiGHT trial) not universally adopted; once-yearly drop (latanoprostene bunod) and sustained-release implants (Durysta) improving adherence
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Glaucoma” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."